Microemulsion technology in the reformulation of cyclosporine: The reason behind the pharmacokinetic properties of Neoral

Clinical Transplantation

Volumn 10, Issue 4, 1996, Pages 364-373

  Ritschel, Wolfgang A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cyclosporine; Microemulsion; Technology; Transplantation

Indexed keywords

CYCLOSPORIN A;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; HUMAN; LIPOPHILICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CAPSULES; CYCLOSPORINE; EMULSIONS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

EID: 0029741995     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. NIES AS. Principles of therapeutics. In: GOODMAN OILMAN A, RALL TW, NIES AS, TAYLOR P. eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: McGraw Hill Inc. 1993.
2. KOCH-WESER J. Serum drug concentrations as therapeutic guides. N Engl J Med 1972: 287: 227.
3. BENET LZ, MITCHELL JR, SHEINER LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: GOODMAN LS, GILMAN A, RALL TW, NIES AS, TAYLOR P. eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: McGraw Hill Inc. 1990.
4. LINN EE, POHLAND RC, BYRD TK. Microemulsion for intradermal delivery of cetyl alcohol and octyl dimethyl PABA. Drug Dev Ind Pharm 1990: 16: 899.
5. RITSCHEL WA. Microemulsions for improved peptide absorption from the gastrointestinal tract. Meth Find Exp Clin Pharmacol 1991: 13: 205.
6. LUNDBERG B. Techniques for complexing pharmacological agents to lipoproteins and lipid microemulsions. In: SHAW JM, ed. Lipoproteins as Carriers of Pharmacological Agents. New York: Marcel Dekker Inc. 1991.
7. RITSCHEL WA. Targeting in the gastrointestinal tract: new approaches. Meth Find Exp Clin Pharmacol 1991: 13: 313.
8. RITSCHEL WA. The alimentary canal: a challenge for drug targeting. In: Proceedings of 10th anniversary conference of the Academy of Pharmaceutical Sciences; Potchefstroom, South Africa. 1990: 108.
9. RITSCHEL WA. Gastrointestinal absorption of peptides using microemulsions as delivery systems. Bull Technol Gattefosse 1990: 83: 7.
10. VERHOEF JC, BODDE HE, DE BOER AG, et al. Transport of peptide and protein drugs across biological membranes. Eur J Drug Metab Pharmacokinet 1990: 15: 83.
11. RAO S. RITSCHEL WA. Colonic drug delivery of small peptides. S T P Pharma Sciences 1995: 190
12. DAVIS SS. The oral delivery of peptides and proteins. Bull Technol Gattefosse 1993: 86: 9.
13. OSBORNE DW, WARD AJI, O'NEILL KJ. Microemulsions as topical drug delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug. J Pharm Pharmacol 1991: 43: 451.
14. WOOD AJ, MAURER G. NIEDERBERGER W. BEVERIDGE T. Cyclosporine: pharmacokinetics, metabolism, and drug interactions. Transplant Proc 1983: 15 (suppl 1): 2409.
15. KAHAN BD. Role of cyclosporine: present and future. Transplant Proc 1994: 26: 3082.
16. KAHAN BD, WELSH M, RUTZKY L, et al. The ability of pre-transplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992: 53: 345.
17. SCHROEDER TJ, HARIHARAN S. FIRST MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994: 26: 2787.
18. LINDHOLM A, KAHAN BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993: 54: 205.
19. KAHAN BD, DUNN J. FITTS C, et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994: 26: 2940.
20. LEVY G. GRANT D. Potential for CsA-Neoral in organ transplantation. Transplant Proc 1994: 26: 2932.
21. KOVARIK JM, MUELLER EA, JOHNSTON A, HITZENBERGER G. KUTZ K. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993: 13: 613.
22. VONDERSCHER J. MEINZER A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994: 26: 2925.
23. MUELLER EA, KOVARIK JM, VAN BREE JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994: 11: 301.
24. HOLT DW, MUELLER EA, KOVARIK JM, VAN BREE JB, KUTZ K. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc 1994: 26: 2935.
25. KOVARIK JM, MUELLER EA, VAN BREE JB, TETZEOFF W. KUTZ K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994: 83: 444.
26. MUELLER EA, KOVARIK JM, VAN BREE JB, et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the marketformulation.Pharm Res 1994: 11: 151.
27. MUELBER EA, KOVARIK JM, VAN BREE JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994: 57: 1178.
28. KOVARIK JM, MUELLER EA, VAN BREE JB, ARNS W. RENNER E, KUTZ K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994: 16: 232.
29. FIOCCHI R. MAMPRIN F. GAMBA A, et al. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 1994: 26: 2994
30. TRULL AK, TAN KKC, TAN L, ALEXANDER GJM, JAMIESON NV. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant Proc 1994: 26: 2977.
31. FREI U. TAESCH S. NIESE D for the International Sandimmun Neoral Study Group. Use of Sandimmun Neoral in renal transplant patients. Transplant Proc 1994: 26: 2928.
32. LEVY G. ROCHON J. FREEMAN D, et al. Cyclosporine Neoral in liver transplant recipients. Transplant Proc 1994: 26: 2949.
33. NIAZI S. Delivery of drugs: introduction and formulation factors. Textbook of Biopharmaceutics and Clinical Pharmacokinetics. New York: Appleton-Century-Crofts, 1979.
34. ABDOU HM. Bioequivalence - case histories. Dissolution, Bioavailability & Bioequivalence. Easton, Penn: Mack Publishing Co, 1989.
35. JOUNELA AJ, PENTIKAINEN PJ, SOTHMANN A. Effect of particle size on the bioavailability of digoxin. Eur J Clin Pharmacol 1975: 8: 365.
36. BARRETT WE, HANIGAN JJ. The bioavailability of griseofulvin PEG ultramicrosize (Gris-PEG) tablets in man under steady-state conditions. Curr Ther Res 1975: 18: 491.
37. PETTIT JHS. Comparative trial of fine-particle griseofulvin in favus. Brit J Dermatol 1962: 74: 62.
38. HARVEY G. ALEXANDER J O'D. Griseofulvin in fungous diseases of the skin. Lancet 1962: 1: 327.